AstraZeneca Loses One Prilosec Patent: Three Others To Be Decided By Aug.
Executive Summary
A decision on the relevance of AstraZeneca's antibiotic-related patents for the proton pump inhibitor Prilosec (omeprazole) is expected by August.
You may also be interested in...
Dr. Reddy’s Omeprazole Case Vs. FDA Challenges Patent-By-Patent Exclusivity
Dr. Reddy's omeprazole case against FDA challenges the agency's decision to award exclusivity on a patent-by-patent basis
Dr. Reddy’s Omeprazole Case Vs. FDA Challenges Patent-By-Patent Exclusivity
Dr. Reddy's omeprazole case against FDA challenges the agency's decision to award exclusivity on a patent-by-patent basis
Prilosec Summary Judgment Narrows Scope Of Patent Infringement Case
AstraZeneca's delayed-release formulation patents for its gastric ulcer drug Prilosec will be the focus of patent infringement litigation after a federal court dismissed as invalid one of the company's "method of treatment" patents.